Evidence map›Paper›PMID 9256429›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1997

SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia.

S H Hong, G David, C W Wong, A Dejean, M L Privalsky

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 343 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Function of PML-RARA in Acute Promyelocytic Leukemia.Advances in experimental medicine and biology · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Advances of Zinc Signaling Studies in Prostate Cancer.International journal of molecular sciences · 2020
    Review
  18. Article
  19. Article
  20. Review

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

S H HongSection of Microbiology, Division of Biological Sciences, University of California, Davis, CA 95616, USA.
G David
C W Wong
A Dejean
M L Privalsky
Inserm · FRInstitut Pasteur · FR

Funding

MECHANISM OF ACTION OF THE VERB A ONCOGENE OF AEVR37CA053394 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI PRIVALSKY, MARTIN L. · 1994 to 2012
$3.4M
NCI NIH HHS R37 CA053394NCI NIH HHS R37 CA-53394
6 · The paper itself

Abstract

Retinoic acid receptors (RARs) are hormone-regulated transcription factors that control key aspects of normal differentiation. Aberrant RAR activity may be a causal factor in neoplasia. Human acute promyelocytic leukemia, for example, is tightly linked to chromosomal translocations that fuse novel amino acid sequences (denoted PML, PLZF, and NPM) to the DNA-binding and hormone-binding domains of RARalpha. The resulting chimeric receptors have unique transcriptional properties that may contribute to leukemogenesis. Normal RARs repress gene transcription by associating with ancillary factors denoted corepressors (also referred to as SMRT, N-CoR, TRAC, or RIP13). We report here that the PML-RARalpha and PLZF-RARalpha oncoproteins retain the ability of RARalpha to associate with corepressors, and that this corepressor association correlates with certain aspects of the leukemic phenotype. Unexpectedly, the PLZF moiety itself can interact with SMRT corepressor. This interaction with corepressor is mediated, in part, by a POZ motif within PLZF. Given the presence of POZ motifs in a number of known transcriptional repressors, similar interactions with SMRT may play a role in transcriptional silencing by a variety of both receptor and nonreceptor transcription factors.

Indexed as

DNA-Binding ProteinsHumansKruppel-Like Transcription FactorsLeukemia, Promyelocytic, AcuteNuclear Receptor Co-Repressor 2Oncogene ProteinsPromyelocytic Leukemia Zinc Finger ProteinReceptors, Retinoic AcidRecombinant Fusion ProteinsRepressor ProteinsRetinoic Acid Receptor alphaSignal TransductionTranscription FactorsTranscription, GeneticTumor Cells, CulturedDNA-Binding ProteinsKruppel-Like Transcription FactorsNCOR2 protein, humanNuclear Receptor Co-Repressor 2Oncogene ProteinsPromyelocytic Leukemia Zinc Finger ProteinRARA protein, humanReceptors, Retinoic AcidRecombinant Fusion ProteinsRepressor ProteinsRetinoic Acid Receptor alphaTranscription FactorsZBTB16 protein, human

Identifiers

PMID9256429
PMCPMC23013
OpenAlexW2038499121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.